

## Synthetic and Adenovirus Delivered Small Interference RNA Pools Targeting Conserved Regions of Foot-and-Mouth Disease Virus

Su-Mi Kim<sup>1,2</sup>, Kwang-Nyeong Lee<sup>1</sup>, Young-Joon Ko<sup>1</sup>, Yi-Seok Joo<sup>1</sup>,  
Hyun-Soo Kim<sup>2</sup> and Jong-Hyeon Park<sup>1\*</sup>

<sup>1</sup>Foreign Animal Disease Division, National Veterinary Research and Quarantine Service,  
Ministry for Food, Agriculture, Forestry and Fisheries, Anyang, Korea

<sup>2</sup>Department of Veterinary Medicine, Chungnam National University, Daejeon, Korea

Foot-and-mouth disease (FMD) is an economically significant animal disease because of the speed of its transmission. Routine vaccination may not be effective for early protection in an outbreak situation. Small interfering RNA (siRNA) can be used as a rapid, effective, and an alternative antiviral approach. In this study, we screened 15 synthetic siRNAs to inhibit FMD virus replication in IBRS-2 cells and selected 10 siRNA sequences. Furthermore, we produced 7 adenoviruses expressing shRNA targeting conserved regions of FMDV, such as a leader sequence and nonstructural protein regions, and showed their antiviral effects. We compared the antiviral effects among them and compared between synthetic siRNAs and adenovirus-delivered siRNAs. In particular, the most efficient siRNA, 3C<sub>2</sub>, was the conserved sequence in the O, A, Asia 1, and C serotypes of FMDV and was located in the predicted loop structure. The pool of sequences including 3C<sub>2</sub> and recombinant adenoviruses could be applied for multiple siRNAs and protection in a broad range of cells and animals.

**Key Words:** siRNA; Pool; Adenovirus; Antiviral effects

### INTRODUCTION

Foot-and-mouth disease (FMD) is a highly contagious disease that affects cloven-hoofed animals such as cattle, swine, and sheep (1). Because FMD virus (FMDV) can spread rapidly between susceptible animals, it is listed by the World Organization for Animal Health (OIE) and is, politically and economically, one of the most important animal diseases in the world. FMDV belongs to the genus

Aphthovirus in the family *Picornaviridae* (2). The virus genome comprises 8.5 kb of positive-sense, single-stranded RNA containing one open reading frame. There are seven serotypes of FMDV: A, O, C, Asia1, SAT1, SAT2, and SAT3, but numerous subtypes have evolved within each serotype (3, 4).

The phenomenon of RNA interference (RNAi) is mediated by a short hairpin dsRNA (shRNA) and causes gene silencing in a sequence-specific manner. The inhibition of virus replication by RNA interference has been reported for several viruses associated with human disease, including poliovirus, human immunodeficiency virus-1, and hepatitis virus (5~9). Recently, inhibition of FMDV replication using RNAi has been reported. Kahana *et al.* demonstrated that RNAi could decrease the replication of FMDV in BHK-21 cells (10). A plasmid expressing shRNA that targets the VP1 region (11) and adenoviruses expressing shRNA that

Received: April 6, 2010/ Revised: November 23, 2010

Accepted: November 30, 2010

\*Corresponding author: Jong-Hyeon Park. Foreign Animal Disease Division, National Veterinary Research and Quarantine Service, Ministry for Food, Agriculture, Forestry and Fisheries, Anyang 430-824, Korea.  
Phone: +82-31-467-1719, Fax: +82-31-449-5882  
e-mail: parkjhvet@korea.kr

\*\*This work was supported by the National Veterinary Research and Quarantine Service (NVRQS), Republic of Korea.

target the 1D and 3D regions (12) have been shown to possess antiviral activity against FMDV *in vitro* and *in vivo*.

The use of current FMD vaccines to induce early protection is limited because complete protection cannot be induced until seven days; alternative methods to rapidly reduce the spread of FMDV in outbreak situations are needed. The application of RNAi is one of the possible alternative strategies for FMDV control because it is a rapid and effective antiviral approach.

Adenovirus vectors have several advantages as a delivery system. They are relatively stable and easy to manipulate and can be obtained in high titers. Adenovirus vectors can be administered by various routes such as intranasal, oral, intraperitoneal, intravenous, intramuscular, and subcutaneous (13), and therefore, can be effectively applied in animals as well. Researchers have reported inhibition of FMDV replication using adenovirus expressing RNAi (12).

In this study, we screened fifteen small interfering RNAs (siRNAs) to inhibit FMDV replication in IBRS-2 cells and selected ten siRNA sequences. Furthermore, we produced seven adenoviruses expressing the shRNA targeting con-

served regions of FMDV and showed their antiviral effects.

## MATERIALS AND METHODS

### Cells, viruses, and virus titration

Human embryonic kidney cells, including human adenovirus type 5 E1 DNA (293 A cells) and swine kidney cells (IBRS-2) were propagated in Dulbecco's modified Eagle's medium (D-MEM) supplemented with 10% fetal bovine serum (FBS, pH 7.4) at 37°C with 5% CO<sub>2</sub>. FMDV isolates of strain O/SKR/2002 (GenBank accession number AY-312588 and AY312589), A22/IRQ (GenBank accession number AY593753), and As/MOG/05 (GenBank accession number EF614458) were used for the viral challenges. Virus titers were determined on IBRS-2 cells for FMDV and 293A cells for adenovirus. The 50% tissue culture infective dose (TCID<sub>50</sub>) was calculated using the formula of Reed and Muench (14).


### Design and synthesis of siRNAs

The siRNAs were developed from FMDV O/SKR/2000

**Table 1.** Target sequences of siRNAs used in this study

Name	Target sequence	The region of FMDV (nt position)
5'U	5'-TGACACTGATACTGGTACT-3'	5'UTR (1058~1076)
L	5'-GTCTACTACTCACCTGAGA -3'	Leader (1301~1319)
VP3	5'-CAITTTCAATCCCTTACCT-3'	VP3 (3069~3087)
VP1 <sub>1</sub>	5'-CTGCTTTACCGCATGAAGA-3'	VP1 (3788~3806)
VP1 <sub>2</sub>	5'-CGGGTGACTGAACTGCTTT-3'	VP1 (3776~3794)
2B	5'-GCAGGAGGACATGTCAACA-3'	2B (4012~4030)
2C <sub>1</sub>	5'-CANATGCAGGAGGACATGT-3'	2C (4007~4025)
2C <sub>2</sub>	5'-CAAATTGGACATCATCAAA-3'	2C (5140~5158)
3C <sub>1</sub>	5'-GAGTGTTTGAGTTTGAGAT-3'	3C (6240~6258)
3C <sub>2</sub>	5'-GACAGTGACTACAGAGTGT-3'	3C (6227~6245)
3D <sub>1</sub>	5'-CTCCATTACCGATGTCACT-3'	3D (7810~7818)
3D <sub>2</sub>	5'-TGTTGAGGAGCGGTACAT-3'	3D (6700~6718)
3D <sub>3</sub>	5'-CACTTTCCTCAAAAGATCT-3'	3D (7825~7843)
3D <sub>4</sub>	5'-GATAGTTGACACCAGAGAT-3'	3D (6682~6700)
3D <sub>5</sub>	5'-GACGACATCGTGGTTGCAA-3'	3D (7688~7706)
con	5'-CCTACGCCACCAATTCGT-3'	Negative control





**Figure 2.** Inhibition of FMDV replication in IBRS-2 cells by synthesized siRNA. IBRS-2 cells were transfected with 10 nM of each siRNA including negative control siRNA. After 12 h of transfection, the IBRS-2 cells were infected immediately with 100 TCID<sub>50</sub> of FMDV (O/SKR/2002). The relative viral level was measured at 48 h p.i. using antigen ELISA (\**p* < 0.05, t-test, a statistically significant differences between negative control (con) and others). Optical density (OD) was changed to relative antigen level (%) which was percentage of sample OD to negative control OD. Error bars indicate standard deviation (SD).

10<sup>6</sup> TCID<sub>50</sub>. After 12 h of adsorption, the Ad-shRNA suspension was removed and the cells were washed twice with D-MEM. The IBRS-2 cells were infected immediately with 100 µl (100 TCID<sub>50</sub>/0.1 ml) of FMDV (this was performed 12 h postinoculation with adenoviruses). After 1 h of adsorption at 37°C, the inocula were removed and the cells were washed twice with D-MEM. Two hundred microliters of culture medium containing 2% FBS were added and the cells were incubated at 37°C. Supernatants were collected at 48 h after FMDV infection and were used in the kinetic analysis of FMDV.

#### Analysis of FMDV replication in IBRS-2 cells

To assay the effect of siRNA or adenovirus-mediated shRNA on FMDV RNA replication, FMDV antigen enzyme-linked immunosorbent assay (ELISA) was performed. The level of FMDV antigen in the supernatants was determined by antigen ELISA using a test kit produced by the Pirbright Laboratory, Institute for Animal Health, UK (15). ELISA was repeated three times and optical density (OD) was changed to the relative antigen level (%), which is percentage of sample OD to control OD. T-test was performed for statistical analysis by GraphPad InStat (ver 3.05, GraphPad software, La Jolla, CA, USA).

#### Prediction of RNA secondary structure and sequence alignment


RNA secondary structure of the partial 3C region including 3C<sub>2</sub> siRNA sequences, was obtained from the Mfold web server (<http://bioweb.pasteur.fr/seqanal/interfaces/mfold-simple.html>). Sequence alignment and editing were performed using CLUSTAL W (16) and the BioEdit program (17).

## RESULTS

#### Inhibition of FMDV replication in IBRS-2 cells by synthesized siRNA

The relative viral protein level was measured at 48 h postinfection (p.i.) using FMDV antigen ELISA. The results show that the relative level (%) of FMD viral protein was reduced in IBRS-2 cells transfected with siRNAs (Fig. 2). Ten siRNAs showed antiviral effect compared with the negative control siRNA; the antiviral effect of the other five (2C<sub>1</sub>, 3D<sub>3</sub>, 5'U, 3D<sub>5</sub>, and 2C<sub>2</sub>) was not statistically significant. Among the siRNAs that were found to have antiviral effect, 3C<sub>1</sub>, 3D<sub>1</sub>, 3D<sub>2</sub>, VP1<sub>1</sub>, VP1<sub>2</sub>, 2B, 3C<sub>2</sub>, 3D<sub>4</sub>, and L showed more than 80% reduction compared with the no treatment group (FMDV group). They showed superior

FMDV inhibition effect compared with the negative control siRNA (Con group) and the values are statistically significant ( $p < 0.05$ ). In the cases of VP3 and L, the inhibition effect narrowly satisfied the statistically significant level. Among the ten siRNAs, two siRNAs (VP1<sub>1</sub> and VP1<sub>2</sub>)



**Figure 3.** Inhibition of FMDV replication in IBRS-2 cells by recombinant adenovirus. IBRS-2 cells were infected with Ad-shRNA at  $3 \times 10^6$  TCID<sub>50</sub>. After 12 h of infection, the IBRS-2 cells were infected immediately with 100 TCID<sub>50</sub> of FMDV (O/SKR/2002). The relative viral protein level measured at 48 h p.i. using antigen ELISA (\* $p < 0.05$  and \*\*\* $p < 0.0001$ , t-test, a statistically significant differences between control (Ad-Lamin A/C) and others. Optical density (OD) was changed to the relative antigen level (%), which was percentage of sample OD to negative control OD. Error bars indicate standard deviation (SD).

targeted structural protein, one siRNA (L) targeted leader protease, and the others targeted nonstructural protein regions.

**Inhibition of FMDV replication in IBRS-2 cells by adenovirus-mediated shRNA treatment**


Among the siRNA sequences that showed antiviral effect, we selected those that targeted the leader protease region or the nonstructural protein, which is the conserved region that inhibits against various serotypes of FMDV replication. We constructed a recombinant adenovirus that expressed the selected siRNAs including 3C<sub>1</sub>, 3D<sub>1</sub>, 3D<sub>2</sub>, 2B<sub>1</sub>, 3C<sub>2</sub>, 3D<sub>4</sub>, and L (Fig. 1C). In 48 h FMDV postinfection, Ad-3C<sub>1</sub>, Ad-3D<sub>1</sub>, Ad-3D<sub>2</sub>, Ad-2B<sub>1</sub>, Ad-3D<sub>4</sub>, and Ad-L, all showed statistically significant differences in FMDV replication ( $p < 0.05$ ) (Fig. 3). Furthermore, Ad-3C<sub>2</sub> ( $p < 0.0001$ ) was the most effective.

**Sequence alignment of 3C<sub>2</sub> siRNA region for seven serotypes and predicting the location of 3C<sub>2</sub> siRNA in RNA structure**


We analyzed the 3C<sub>2</sub> siRNA target sequences to anticipate against seven serotypes of FMDV (Fig. 4A). The sequences were completely conserved between the O, A, Asia 1, and

**A**

3C2 target	GACAGTGACTACAGAGTGT
O / SKR / 2002 (AY312589)	.....
A22 / IRQ (AY5937530)	.....
As / MOG / 05 (EF614458)	.....
C3 / Resende (AY593807)	.....
SAT1 / BOT (AY593845)	.. T ..... T .....
SAT2 / ZIM (AF540910)	..... TT .....
SAT3 / ZIM (AY884148)	..... T .....



**Figure 4.** Nucleotide sequence alignment of 3C<sub>2</sub> siRNA region for seven serotypes of FMDV and RNA structure including 3C<sub>2</sub> siRNA region. (A) Sequence alignment and editing were performed using CLUSTAL W (16) and BioEdit program (17). (B) RNA secondary structure of the partial 3C region including 3C<sub>2</sub> siRNA sequences was obtained from the Mfold web server (<http://bioweb.pasteur.fr/seqanal/interfaces/mfold-simple.html>). siRNA 3C<sub>2</sub> sequences are included in the magnified figure and nucleotide T (thymine) represents U (uracil) in the RNA structure. Red lines represent G-C pairs and blue and green lines represent A-U and G-U pairs.



**Figure 5.** Cross-inhibition of Ad-3C<sub>2</sub> against O, A, and Asia 1 type of FMDV in IBRS-2 cells. IBRS-2 cells were infected with Ad-shRNA at  $3 \times 10^6$  TCID<sub>50</sub>. After 12 h of infection, the IBRS-2 cells were infected immediately with 100 TCID<sub>50</sub> of FMDV (O/SKR/2002, A22/IRQ, and Asia 1/MOG/05). The relative viral protein level measured at 24 and 48 h p.i. using antigen ELISA. Optical density (OD) was changed to the relative antigen level (%), which was percentage of sample OD to negative control OD. Error bars indicate standard deviation (SD).

C serotypes of FMDV, but had sequence variation in the SAT 1 (two mismatches), SAT 2 (two mismatches), and SAT 3 (one mismatch) serotypes of FMDV used in this study.

Furthermore, it was predicted that the 3C<sub>2</sub> sequences were located in the loop structure of 3C (Fig. 4B).

#### Antiviral effects of 3C<sub>2</sub> siRNA against O, A, and Asia 1 FMDV

We observed antiviral effects when the adenovirus expressing 3C<sub>2</sub> siRNA was applied to O, A, and Asia 1 serotypes of FMDV (Fig. 5). We analyzed the level of FMDV protein at 24 and 48 h p.i. of FMDV. The replications of A and Asia 1 type were significantly inhibited, as were the O type of FMDV. Their protein levels were less than 30% compared with the Ad-Lamin A/C control at 48 h p.i.

## DISCUSSION

This study screened siRNAs against O/SKR/2002 and O/SKR/2000 of FMDV. We designed 15 siRNA sequences and detected the antiviral effects of 10 siRNAs. It was reported that the siRNA targeting 5'UTR was less efficient than the siRNAs targeting other regions at inducing antiviral activity in poliovirus, another member of the family *Picornaviridae* (5). The siRNA targeting 5'UTR did not show significant antiviral effects in this study. However, the siRNA targeting leader sequence had significant antiviral

effects (Fig. 2).

There are two approaches for RNAi. One is to transfect synthesized siRNAs and the other is to express shRNA using a plasmid vector or a viral vector. Though transfecting synthesized siRNA is a simple method, it cannot offer long-term gene suppression (18); therefore, we produced recombinant adenoviruses with shRNA driven by the U6 promoter in this study. The U6 promoter is known as a well characterized and strong pol III promoter and is more efficient than an H1 promoter (19, 20). Chen *et al.* demonstrated that shRNA targeting VP1 had an antiviral effect against FMDV in suckling mice (11). However, the antiviral effect of shRNA targeting VP1 was serotype specific; furthermore, adenovirus expressing shRNAs targeting the 1D or 3D region of O type of FMDV showed cross inhibition (12). Therefore, we selected seven siRNAs targeting conserved regions, including a leader sequence and nonstructural protein regions for resistance from escape mutants and for cross-protection in several serotypes of FMDV. Though seven recombinant adenoviruses had antiviral effects, the inhibition effects of the adenovirus-mediated shRNAs did not exactly match those of the synthesized siRNAs (Fig. 2 and Fig. 3). Although synthesized siRNAs directly work in cytoplasm, shRNA must be generated in the nucleus before shRNA-mediated viral vectors are able to come out to the cytoplasm. Therefore, even if the same target sequence is expressed, the silencing effect on the target RNA may differ. In this study, 3C<sub>2</sub> was the most effective in approaches for both synthesized

siRNA and adenovirus-mediated shRNA. Because the 3C<sub>2</sub> siRNA sequence was conserved in O, A, Asia 1, and C types of FMDV (Fig. 4A), the interference was maintained in several serotypes. The alignment coincided with the antiviral effects against O, A, and Asia 1 types of FMDV (Fig. 5). In terms of silencing efficiency, it depended on the structural environment of the target site, as well as the siRNA sequence itself (21, 22). The hairpin structures and loops possibly contributed to the inefficacy of the siRNAs. However, we found that the 3C<sub>2</sub>, targeting disordered loop regions, had high efficiency (Fig. 4B). Furthermore, the 3C<sub>1</sub> sequence, the functional siRNA, was located in a hairpin structure (data not shown). In other studies, the silencing of siRNA targeting *cis*-acting replication element (CRE) of human enterovirus B another member of *Picornaviridae* was not hampered by the stem loop structure and the siRNA had a strong antiviral effect (23).

We screened siRNA sequences in the complete genome for inhibiting FMDV replication and produced synthetic siRNAs and recombinant adenovirus expressing siRNAs. We compared the antiviral effects among them and synthetic siRNAs with adenovirus delivered siRNAs. The pool of sequences and recombinant adenoviruses could be applied for multiple siRNAs and protection in a broad range of cells and animals. However, we did not show whether escaped mutants against the siRNAs including 3C<sub>2</sub> were generated and did not test the duration of the silencing effects of synthetic and adenovirus delivered siRNAs. These issues require further study.

## REFERENCES

- 1) Pereira HG. Foot-and-mouth disease animals. New York, NY: Academic Press, 1981:333-63.
- 2) Bachrach HL. Foot-and-mouth disease. *Annu Rev Microbiol* 1968;22:201-44.
- 3) Domingo E, Escarmís C, Baranowski E, Ruiz-Jarabo CM, Carrillo E, Núñez JI, *et al.* Evolution of foot-and-mouth disease virus. *Virus Res* 2003;91:47-63.
- 4) Knowles NJ, Samuel AR. Molecular epidemiology of foot-and-mouth disease virus. *Virus Res* 2003;91:65-80.
- 5) Gitlin L, Stone JK, Andino R. Poliovirus escape from RNA interference: short interfering RNA-target recognition and implications for therapeutic approaches. *J Virol* 2005;79:1027-35.
- 6) Saulnier A, Pelletier I, Labadie K, Colbère-Garapin F. Complete cure of persistent virus infections by antiviral iRNAs. *Mol Ther* 2006;13:142-50.
- 7) Jacque JM, Triques K, Stevenson M. Modulation of HIV-1 replication by RNA interference. *Nature* 2002;418:435-8.
- 8) Lee NS, Rossi JJ. Control of HIV-1 replication by RNA interference. *Virus Res* 2004;102:53-8.
- 9) Hamasaki K, Nakao K, Matsumoto K, Ichikawa T, Ishikawa H, Eguchi K. Short interfering RNA-directed inhibition of hepatitis B virus replication. *FEBS Lett* 2003;543:51-4.
- 10) Kahana R, Nakao K, Matsumoto K, Ichikawa T, Ishikawa H, Eguchi K. Inhibition of foot-and-mouth disease virus replication by small interfering RNA. *J Gen Virol* 2004;85:3213-7.
- 11) Chen W, Yan W, Du Q, Fei L, Liu M, Ni Z, *et al.* RNA interference targeting VP1 inhibits foot-and-mouth disease virus replication in BHK-21 cells and suckling mice. *J Virol* 2004;78:6900-7.
- 12) Chen W, Liu M, Jiao Y, Yan W, Wei X, Chen J, *et al.* Adenovirus-mediated RNA interference against foot-and-mouth disease virus infection both *in vitro* and *in vivo*. *J Virol* 2006;80:3559-66.
- 13) Souza AP, Haut L, Reyes-Sandoval A, Pinto AR. Recombinant viruses as vaccines against viral diseases. *Braz J Med Biol Res* 2005;38:509-22.
- 14) Reed LI, Muench H. A simple method of estimating fifty percent and points. *Am J Hygiene* 1938;27:493-7.
- 15) Roeder PL, Le Blanc Smith PM. Detection and typing of foot-and-mouth disease virus by enzyme-linked immunosorbent assay: a sensitive, rapid and reliable technique for primary diagnosis. *Res Vet Sci* 1987;43:225-32.
- 16) Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. *Nucleic Acids Res* 1994;22:4673-80.

- 17) Hall TA. Bioedit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. *Nucleic Acids Symp Ser* 1999;41:95-8.
  - 18) Root DE, Hacohen N, Hahn WC, Lander ES, Sabatini DM. Genome-scale loss-of-function screening with a lentiviral RNAi library. *Nat Methods* 2006;3:715-9.
  - 19) Lo HL, Chang T, Yam P, Marcovecchio PM, Li S, Zaia JA, *et al.* Inhibition of HIV-1 replication with designed miRNAs expressed from RNA polymerase II promoters. *Gene Ther* 2007;14:1503-12.
  - 20) Makinen PI, Koponen JK, Karkkainen AM, Malm TM, Pulkkinen KH, Koistinaho J, *et al.* Stable RNA interference: comparison of U6 and H1 promoters in endothelial cells and in mouse brain. *J Gene Med* 2006;8:433-41.
  - 21) Schubert S, Grunweller A, Erdmann VA, Kurreck J. Local RNA target structure influences siRNA efficacy: systematic analysis of intentionally designed binding regions. *J Mol Biol* 2005;348:883-93.
  - 22) de Almeida RS, Keita D, Libeau G, Albina E. Structure and sequence motifs of siRNA linked with *in vitro* down-regulation of morbillivirus gene expression. *Antiviral Res* 2008;79:37-48.
  - 23) Lee HS, Ahn J, Jee Y, Seo IS, Jeon EJ, Jeon ES, *et al.* Universal and mutation-resistant anti-enteroviral activity: potency of small interfering RNA complementary to the conserved cis-acting replication element within the enterovirus coding region. *J Gen Virol* 2007;88:2003-12.
-